28th Mar 2006 16:00
AstraZeneca PLC28 March 2006 Transaction by Persons Discharging Managerial ResponsibilitiesDisclosure Rules DR 3.1.2R We hereby inform you that on 24 March 2006, the following individuals, who areall persons discharging managerial responsibilities, were each granted an awardunder the terms of the AstraZeneca Performance Share Plan over the Company'sUSD0.25 Ordinary Shares or, in the case of A Zook, over the Company's AmericanDepositary Shares (ADSs). One ADS equals one Ordinary Share Target number of shares Award price per share awarded Normal vesting dateName of individual B Angelici 26,781 2975p 24 March 2009 A P Bloxham 13,847 2975p 24 March 2009 J Lundberg 18,475 2975p 24 March 2009 M Nicklasson 18,473 2975p 24 March 2009 B J Thorpe 13,834 2975p 24 March 2009 A Zook 37,624 US$51.73 24 March 2009 The AstraZeneca Performance Share Plan was approved by shareholders at theCompany's AGM in 2005. Awards made under the Plan may not generally vest beforethe third anniversary of the relevant date of grant nor unless the specifiedperformance target(s) have been met at the end of the three year period which,for this award, is 1 January 2006 to 31 December 2008. The performance target that applies to this award is the Company's TotalShareholder Return ("TSR") compared to the TSR of a selected peer group of 12other pharmaceutical companies. The actual number of shares to which aparticipant may become unconditionally entitled will depend on the extent towhich the performance target(s) have been met. A summary of the Plan, includinga more detailed explanation of the performance target(s), can be found in theAstraZeneca Annual Report and Form 20-F Information 2005 which is available onthe Company's website www.astrazeneca.com. On 25 March 2005, Anthony Zook, Executive Vice-President, North America, becameunconditionally entitled to a final award of 11,494 American Depositary Shares(ADSs) on the partial vesting of an original target award of 11,973 ADSs, whichwere awarded to him in March 2003 under the terms of the AstraZeneca USExecutive Performance Share Plan. Mr Zook has ceased to have an interest in the479 ADSs of the original target award that did not vest. The closing price ofAstraZeneca ADSs on 24 March 2006 was US$51.73. One ADS equals one OrdinaryShare. G H R MuskerCompany Secretary28 March 2006 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca